FDA Approves Rituximab Combination Across Multiple Pediatric Cancer Indications
December 3rd 2021FDA approves rituximab (Rituxan) plus chemotherapy for pediatric patients with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia.
Read More
Considerations for Environmentally Conscious Pharmacy Students
Environmental conditions and air pollution affect health by causing injuries and fatalities, exacerbating respiratory and cardiovascular diseases, and spreading infectious diseases.
Read More
Experts Discuss How Pharmacists Can Help Fight Opioid Addiction
December 2nd 2021Jaime Bridges, opioid outreach coordinator at Orlando Health Orlando Regional Medical Center, and Kris Smith, PharmD, clinical pharmacy specialist for internal medicine at Orlando Health Orlando Regional Medical Center discuss how COVID-19 has affected the opioid crisis and what opioid-free pain management options are available as alternatives.
Read More
FDA Approves Daratumumab Triplet Combo for Relapsed/Refractory Multiple Myeloma
December 2nd 2021The combination of daratumumab with hyaluronidase (Darzalex Faspro), hyaluronidase-fihj, carfilzomib (Kyprolis), and dexamethasone is indicated for the treatment of adult patients with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy.
Read More